The ESC Textbook of Cardiovascular Medicine

Γίνε ο πρώτος που θα αξιολόγησει αυτό το προϊόν

Συγγραφείς:: A. John Camm , Thomas F. Lüscher , Gerald Maurer , Patrick W. Serruys

ISBN: 9780198784906

This new, third edition of The ESC Textbook of Cardiovascular Medicine is a ground-breaking initiative from the European Society of Cardiology that transforms reference publishing in cardiovascular medicine to better serve the changing needs of the global cardiology community. Providing the background information behind clinical practice and the ESC Clinical Practice Guidelines, this publication is an invaluable resource for cardiologists across the world.

€279,50

Ποσότητα:

+ -

Provides the background information behind clinical practice through in-depth, peer-reviewed chapters, and broad coverage of the field
Includes contributions from more than 1000 of the world's leading specialists in cardiology
Accompanied by free access to the digital publication, ESC CardioMed, which will be continually updated by the author team
Highly illustrated with multi-media features, including over 350 videos, embedded in the text
Cross-referenced links to ESC Clinical Practice Guidelines, related content, and primary research data in European Heart Journal via ESC CardioMed

New to this Edition:

Completely revamped table of contents covering over 63 disciplines within cardiology
Now split into six key parts: Introduction to the cardiovascular system; Investigations; Heart diseases; Vascular disease; Specific populations - gender and race; and Other aspects of cardiology

Περιγραφή
Περιεχόμενα
Λοιπά στοιχεία
Αξιολογήσεις
Ρωτήστε μας

Provides the background information behind clinical practice through in-depth, peer-reviewed chapters, and broad coverage of the field
Includes contributions from more than 1000 of the world's leading specialists in cardiology
Accompanied by free access to the digital publication, ESC CardioMed, which will be continually updated by the author team
Highly illustrated with multi-media features, including over 350 videos, embedded in the text
Cross-referenced links to ESC Clinical Practice Guidelines, related content, and primary research data in European Heart Journal via ESC CardioMed

New to this Edition:

Completely revamped table of contents covering over 63 disciplines within cardiology
Now split into six key parts: Introduction to the cardiovascular system; Investigations; Heart diseases; Vascular disease; Specific populations - gender and race; and Other aspects of cardiology

PART 1. Introduction to the cardiovascular system
Section 1. Cardiovascular history and physical examination
Section editor: Nicholas Boon
1.1: Andrew Elder, Nicholas A. Boon, and Alan G. Japp: Approach to cardiovascular assessment
1.2: Alan G. Japp, Iain Simpson, Stephen Pettit, Arthur Yue, and Junaid Zaman: Cardiovascular symptoms
1.3: Stuart Pringle, Samantha Fitzsimmons, Ingibjorg Gudmundsdottir, and Joseph B. Esterson: Cardiovascular signs
Section 2. Developmental biology of the heart
Section editor: Miguel Torres
2.1: Robert G. Kelly: Cardiac embryogenesis
2.2: Miguel Torres: The molecular basis of cardiac embryogenesis
2.3: Maurice J. B. van den Hoff and Antoon F. M. Moorman: From heart-forming region to ballooning chambers
2.4: José M. Pérez-Pomares and José L. de la Pompa: Development of the ventricles and valves
2.5: Jan Hendrik van Weerd and Vincent M. Christoffels: Development of the cardiac conduction system
2.6: Thomas J. Cahill and Paul R. Riley: Epicardial and coronary vascular development
2.7: Mark H. Soonpaa and Loren J. Field: Cardiomyocyte development from mid-gestation through preadolescence
Section 3. Functional anatomy of the heart
Section editor: Siew Yen Ho
3.1: Sabine Ernst and Siew Yen Ho: Introduction
3.2: Ammar M. Killu and Samuel J. Asirvatham: Cardiac anatomy in the interventional era: an overview
3.3: Taka-aki Matsuyama and Hatsue Ishibashi-Ueda: Normal conduction system, coronary arteries, and coronary veins
3.4: Damian Sanchez-Quintana and José Angel Cabrera: Normal atrial and ventricular myocardial structures
3.5: Philip J. Kilner and Sonya V. Babu-Narayan: The heart as a functional unit
3.6: Philip J. Kilner and Sonya V. Babu-Narayan: Ventricular structure and function
3.7: Luigi Badano and Denisa Muraru: Functional anatomy of atria
3.8: Fahd Makhdom, Pascal Thériault-Lauzier, Siew Yen Ho, and Nicolo Piazza: Functional anatomy of left heart valves
3.9: Christine Selton-Suty, Olivier Huttin, Clément Venner, and Yves Juillière: Functional anatomy of right heart valves
3.10: Robert Manka and Sabrina Oebel: Functional anatomy of myocardial perfusion
Section 4. Cardiovascular physiology
Section editor: Guido Grassi
4.1: Sándor J. Kovács: The heart as a pump: governing principles
4.2: Marek Malik: Cardiac electrophysiology
4.3: Christian Seiler: Cardiovascular physiology: regulation of coronary circulation
4.4: Gino Seravalle and Guido Grassi: Regulation of blood pressure
4.5: Markus P. Schlaich: Heart/kidney interactions
4.6: Ross Arena, Dejana Popovic, Marco Guazzi, Amy McNeil, and Michael Sagner: Cardiovascular response to exercise
4.7: Jens Barthelmes and Isabella Sudano: Cardiovascular response to mental stress
4.8: Naima Covassin and Virend K. Somers: The cardiovascular system during sleep
4.9: Magnus Bäck, Laure Joly, Nicolas Sadoul, and Athanase Benetos: The ageing heart
4.10: Sebastian Ewen, Saarraaken Kulenthiran, and Felix Mahfoud: Alterations in cardiovascular physiology in pathological states
Section 5. Cardiovascular pharmacology
Section editor: Faiez Zannad
5.1: João Pedro Ferreira and Patrick Rossignol: Renin-angiotensin system and neprilysin
5.2: Faiez Zannad and João Pedro Ferreira: Mineralocorticoid receptor antagonists
5.3: Atul Pathak: Autonomic nervous system drugs
5.4: Stéphane Laurent: Pharmacology of vasodilators
5.5: Mattia Arrigo and Alexandre Mebazaa: Positive inotropes
5.6: Federico Guerra and Alessandro Capucci: Antiarrhythmics
5.7: Tabassome Simon: Pharmacology of oral antiplatelet drugs
5.8: Freek W. A. Verheugt: Fibrinolytic therapy
5.9: Cesare R. Sirtori and Massimiliano Ruscica: Lipid-lowering drugs
5.10: Pierre-Jean Saulnier and Samy Hadjadj: Oral diabetes treatments and cardiovascular disease
5.11: Kevin Damman: Renal pharmacology for the cardiologist
5.12: Keld P. Kjeldsen, Juan Tamargo, and Thomas Andersen Schmidt: Potassium binders
5.13: Pauline Bosco-Levy, Julien Bezin, Francesco Salvo, and Nicholas Moore: Cardiovascular effects of non-cardiovascular drugs
5.14: Jeffrey K. Aronson: Drug-drug interactions
5.15: Jonathan Michel and Robert A. Byrne: Local drugs in interventional cardiology pharmacology
Section 6. Anticoagulation
Section editor: Raffaele DeCaterina
6.1: Pier Mannuccio Mannucci: An overview of haemostasis, in relation to atherothrombotic, thromboembolic, and venous cardiovascular disease
6.2: Fedor Bachmann: Current targets of anticoagulants
6.3: Renate Schnabel, Dipak Kotecha, and Paulus Kirchhof: Epidemiology of non-vitamin K antagonist oral anticoagulants in heart disease
6.4: Freek W. A. Verheugt: Unfractionated heparin
6.5: Paul Guedeney, Mathieu Kerneis, Johanne Silvain, Gilles Montalescot, and Jean-Philippe Collet: Low-molecular-weight heparin
6.6: Michiel Coppens: Fondaparinux and its derivatives
6.7: Davide Capodanno: Bivalirudin and argatroban
6.8: Marcel Levi: Reversal of parenteral anticoagulants
6.9: Jørgen Jespersen and Jane Skov: Vitamin K antagonists
6.10: Thomas Vanassche and Peter Verhamme: The NOACs: pharmacodynamics and pharmacokinetics
6.11: Jeffrey Weitz: The NOACs: clinical pharmacology
6.12: Felicita Andreotti, Eliano Pio Navarese, and Filippo Crea: The NOACs in special situations: the elderly, renal impairment, and combination with antiplatelet agents or thrombolysis
6.13: Joanne van Ryn: Reversal of oral anticoagulants
6.14: Christina Reith and Colin Baigent: Epidemiological data on the use of traditional anticoagulants in cardiovascular disease
Section 7. Epidemiology and global burden
Section editor: Sumeet Chugh
7.1: Sumeet S. Chugh: Strategies for assessment of global disease burden
7.2: George A. Mensah: Epidemiology and global burden of hypertension
7.3: Andrew E. Moran: Epidemiology and global burden of ischaemic heart disease
7.4: James D. Wilkinson, Ashwin Kumar, Joslyn A. Westphal, Jason D. Czachor, Hiedy Razoky, and Steven E. Lipshultz: Epidemiology and global burden of cardiomyopathy
7.5: Aapo L. Aro and Sumeet S. Chugh: Epidemiology and global burden of arrhythmias
7.6: Dianne Sika-Paotonu, Andrea Beaton , and Jonathan Carapetis: Epidemiology and global burden of rheumatic heart disease
7.7: Siva Ketha and Leslie T. Cooper: Epidemiology and global burden of myocarditis and pericarditis
7.8: Imad M. Tleyjeh and Aref A. Bin Abdulhak: Epidemiology and global burden of infective endocarditis
7.9: Holger Reinecke: Epidemiology and global burden of peripheral arterial disease and aortic aneurysms
PART 2. Investigations
Section 8. Electrocardiogram
Section editor: Antonio Bayes de Luna
8.1: Antonio Bayes de Luna: Introduction
8.2: Adrian Baranchuk and Bryce Alexander: Atrial abnormalities
8.3: Ljuba Bacharova and Harvey Estes: Ventricular hypertrophy
8.4: Antonio Bayes de Luna and Marcelo Elizari: Intraventricular conduction disturbances
8.5: Miguel Fiol and Antonio Bayes de Luna: ECG patterns of ischemia and necrosis
8.6: Wojciech Zareba and Pyotr Platonov: ECG patterns related to arrhythmias and sudden death: channelopathies, early repolarization, and preexcitiation
8.7: Angel Moya: ECG in syncope, palpitations, dyspnea and chest pain
8.8: Antonio Bayes de Luna and Günter Breithardt: The ECG abnormal in patients without heart disease and the ECG normal in presence of evident structural heart disease
Section 9. Chest radiography
Section editor: Christian Herold
9.1: Christian Loewe and Dietrich Beitzke: Normal anatomy with a focus on the cardiac silhouette and the great vessels
9.2: Massimo Pistolesi and Mariaelena Occhipinti: Pulmonary venous hypertension
9.3: Thomas Henzler: Pulmonary arterial hypertension and acute and chronic thromboembolism
9.4: Tomas Franquet: Pulmonary infections
9.5: Nicola Sverzellati, Gianluca Milanese, and Mario Silva: Focal abnormalities
9.6: Nicholas Screaton and Gianluca Milanese, and Mario Silva: Lines, tubes, and implantable devices
Section 10. Cardiac ultrasound
Frank Flachskampf
10.1: Jens-Uwe Voigt: Principles of echocardiographic imaging and velocity assessment by Doppler and speckle tracking
10.2: Thomas Binder: Technical equipment for echocardiography
10.3: Thomas Binder: Transthoracic echocardiography and the standard examination of specific cardiac structures
10.4: Roxy Senior and Nikolaos Karogiannis: Stress echocardiography
10.5: Anastasia Vamvakidou and Roxy Senior: Contrast echocardiography
10.6: Francesco F. Faletra, Laura A. Leo, Tiziano Moccetti, and Mark J. Monaghan: Three-dimensional echocardiography
10.7: Thomas H. Marwick: Coronary heart disease
10.8: Laura Ernande: Hypertension and diabetes
10.9: Ruxandra Beyer and Frank A. Flachskampf: Transoesophageal echocardiography
10.10: Jens-Uwe Voigt: Left ventricular function, heart failure, and resynchronization therapy
10.11: Satoshi Nakatani: Assist devices
10.12: Thor Edvardsen: Cardiomyopathies, myocarditis, and the transplanted heart
10.13: Damien Voilliot and Patrizio Lancellotti: Cardiac valves
10.14: Mehdi Eskandari and Mark J. Monaghan: Echocardiography in transcatheter aortic valve implantation
10.15: Mehdi Eskandari and Mark J. Monaghan: Transcatheter mitral valve repair: from edge-to-edge to annuloplasty
10.16: Felix C. Tanner and Rolf Jenni: Prosthetic valve evaluation
10.17: Petros Nihoyannopoulos and Julia Grapsa: Pulmonary hypertension and the right ventricle
10.18: Arturo Evangelista and José Rodríguez-Palomares: Echocardiographic assessment: diseases of the aorta
10.19: Bogdan Popescu, Maria-Magdalena Gurzun, and Carmen Ginghina: Atrial fibrillation
10.20: Aleksandar N. Neskovic, Ivan Stankovic and Predrag Milicevic: Emergency echocardiography
Section 11. Cardiovascular magnetic resonance
Section editor: Dudley Pennell
11.1: Alicia Maceira: Normal anatomy and function
11.2: Sonia Nielles-Vallespin: Cardiovascular magnetic resonance physics, techniques, and contrast agents
11.3: Jurg Schwitter: Coronary artery disease
11.4: Matthias Friedrich and Fabian Siepen: Cardiomyopathies
11.5: Sonya Babu-Narayan: Congenital heart disease
11.6: Saul Myerson: Valvular heart disease
11.7: Chun Yuan, Zach Miller, and Jianming Cai: Atherosclerosis imaging
11.8: Jan Bogaert: Angiography
11.9: Massimo Lombardi and Antonia Camporeale: Less common pathologies
Section 12. Cardiovascular computed tomography
Section editor: Stephan Achenbach
12.1: Stephan Achenbach: Technology of cardiac computed tomography
12.2: Todd C. Villines, Joshua Mitchell, and Michael K. Cheezum: Coronary calcium
12.3: Koen Nieman: Coronary computed tomography angiography: detection of coronary artery stenosis
12.4: Pál Maurovich-Horvat: Coronary computed tomography angiography: imaging of coronary atherosclerotic plaque
12.5: Amita Singh, Noreen Nazir, Victor Mor-Avi, and Amit R. Patel: Computed tomography myocardial perfusion
12.6: Victoria Delgado: Computed tomography for cardiac morphology, function, and valve disease
12.7: Mohamed Marwan and Stephan Achenbach: Computed tomography for cardiac interventions
Section 13. Nuclear cardiology and positron emission tomography
Section editor: Philipp Kaufmann
13.1: Alessia Gimelli and Riccardo Liga: Basic principles and technological state of the art: SPECT
13.2: Frank Bengel: Basic principles and technological state of the art: PET
13.3: Ronny R. Buechel and Aju P. Pazhenkottil: Basic principles and technological state of the art: hybrid imaging
13.4: Juhani Knuuti, S. Richard Underwood, and Antti Saraste: Assessment of coronary artery disease: chronic stable angina
13.5: Juhani Knuuti, S. Richard Underwood, and Antti Saraste: Assessment of coronary artery disease: imaging-guided management and therapy
13.6: Danilo Neglia and Juhani Knuuti: Integration of stress nuclear imaging in the diagnostic and management algorithms of stable coronary artery disease
13.7: Danilo Neglia and Juhani Knuuti: Assessment of coronary artery disease: nuclear myocardial perfusion imaging in specific patient populations
13.8: Danilo Neglia and Oliver Gaemperli: Heart failure
13.9: Fabien Hyafil, Dominique Le Guludec, and Oliver Gaemperli: Endocarditis and device infection
13.10: Tobias A. Fuchs and Oliver Gaemperli: Infiltrative disease (amyloidosis/sarcoidosis)
13.11: Philipp A. Kaufmann, Oliver Gaemperli, and Juhani Knuuti: Future potential
Section 14. Invasive imaging haemodynamics
Section editor: Carlo Di Mario
14.1: Guy Heyndrickx and Carlo Di Mario: Invasive Imaging and Haemodynamics
14.2: Carlo Di Mario, Serafina Valente, and Carlotta Sorini Dini: Coronary Angiography and Ventriculography
14.3: Philip Dingli, Nicola Ryan, Nieves Gonzalo, and Javier Escaned: Intravascular ultrasound imaging
14.4: Francesco Prati, Laura Gatto, Enrico Romagnoli, and Luca Di Vito: Optical coherence tomography
14.5: Carlo Di Mario, Carlotta Sorini Dini, and Serafina Valente: Near InfraRed Spectroscopy
14.6: Emanuele Barbato and Fabio Mangiacapra: Functional coronary assessment: FFR
14.7: Justin Davies and Christopher Cook: Functional coronary assessment: iFRand other indices
Section 15. Selection of imaging techniques
Section editor: Jeroen Bax
15.1: Jeroen J. Bax, Alexander R. van Rosendael, Laurens F. Tops, Nina Ajmone Marsan, and Victoria Delgado: Choice of imaging techniques
PART 3. Heart Diseases
Section 16. Genetics of CV diseases
Section editor: Heribert Schunkert
16.1: Heribert Schunkert: Introduction
16.2: Jodie Ingles, Charlotte Burns, and Laura Yeates: Genetic counselling
16.3: Eric Sijbrands: Principles of cascade screening
16.4: Eric Schulze-Bahr: Principles of molecular testing
16.5: Eric Schulze-Bahr: Basic principles of genetic disease
16.6: Andrea Mazzanti, Riccardo Maragna, and Sylvia Priori: The Genetics of Long QT Syndrome
16.7: Erol Tülümen and Martin Borggrefe: Monogenic and oligogenic CV diseases - Genetics of arrhythmias - short QT Syndrome
16.8: Sonia Van Dooren, Dorien Daneels, Gudrun Pappaert, Maryse Bonduelle, and Pedro Brugada Terradellas: Monogenic and oligogenic CV diseases - Genetics of arrhythmias - Brugada Syndrome
16.9: Peter Schwartz and Lia Crotti: Monogenic and oligogenic CV diseases - Genetics of arrhythmias - catecholaminergic polymorphic ventricular tachycardia
16.10: Najim Lahrouchi, Elijah Behr, and Connie Bezzina: Post-mortem genetic testing in sudden death cases
16.11: Philippe Charron and Carole Maupain: Genetics of cardiomyopathies - Hypertrophic cardiomyopathy
16.12: Daniel Oehler, Benjamin Meder, and Hugo Katus: Genetics of cardiomyopathies - Dilated cardiomyopathy
16.13: Eloisa Arbustini, Alessandro Di Toro, Lorenzo Giuliani, Nupoor Narula, Valentina Favalli: Left Ventricular Noncompaction
16.14: Kalliopi Pilichou, Cristina Basso, Rudy Celeghin, and Gaetano Thiene: Genetics of cardiomyopathies - Arrhythmogenic Right Ventricular Cardiomyopathy
16.15: Abdallah Fayssoil: Genetics of cardiomyopathies -Cardiac manifestations of mitochondrial diseases
16.16: Frank Weidemann: Genetics of cardiomyopathies - Myocardial infiltration
16.17: Dorien Schepers and Bart Loeys: Genetics of vascular diseases - Marfan syndrome and aortic diseases
16.18: Daniela Barge-Schaapveld, Marco DeRuiter, Conny van Munsteren, and Monique Jongbloed: Structural diseases of the heart - Genetics of congenital heart diseases
16.19: Sabine Klaassen: Structural diseases of the heart- Syndromes affecting the CV System
16.20: Heribert Schunkert: Complex Cardiovascular Diseases - Atherosclerosis - genetic factors
16.21: Daniel Swerdlow, Steve Humphries, and Michael Holmes: Complex Cardiovascular Diseases - Dyslipidaemias - genetic factors
16.22: Patrick Ellinor and Steven Lubitz: Genetic Determinants of Atrial Fibrillation
16.23: Georg Ehert: The genetics of arterial hypertension
Section 17. Congenital heart disease (GUCH)
Section editor: John Deanfield
17.1: John Deanfield: Introduction
17.2: John Deanfield and Robert Andersen: Nomenclature
17.3: John Deanfield and Bernard Keavney: Epidemiology and incidence
17.4: Bernard Keavney and Elisavet Fotiou: Genetics
17.5: Marietta Charakida: Fetal circulation & perinatal programming
17.6: John Deanfield: Clinical Presentations & Initial Investigations
17.7: Jan Marek, Folkert Meijboom, and Luc Mertens: Echocardiography in Congenital Heart Disease
17.8: Giovanni Biglino, Silvia Schievano, and Andrew Taylor: Cross-Sectional imaging/modelling
17.9: Alessandro Giardini: Functional Testing
17.10: Henry Chubb and Martin Lowe: Arrhythmias in Childhood and Patients with Congenital Heart Disease
17.11: Shakeel Qureshi: Interventional catheterization
17.12: Michiel Winter, Berto Bouma, Barbara Mulder: Long term Outcomes
17.13: Marietta Charakida: Arterial Disease in the Young
17.14: Jolien Roos-Hesselink and Lucia Baris: Contraception and pregnancy
17.15: Shahin Moledina: Pulmonary Hypertension
17.16: Marc Gewillig: Heart Failure
17.17: Dilveer Panesar and Mike Burch: Support/Transplant
17.18: Marc Gewillig: Atrial Septal Defect (ASD)
17.19: Michelle Carr: Atrioventricular Septal Defect (AVSD)
17.20: Orla Franklin: Ventricular Septal Defect (VSD)
17.21: Robert Yates: Patent Ductus Arteriosus (PDA)
17.22: Robert Yates: Pulmonary Valve (PV) Stenosis
17.23: Robert Yates: Vascular Rings
17.24: David Anderson: Aortic Stenosis (AS) and Left Ventricular Outflow Tract Obstruction (LVOTO)
17.25: Marietta Charakida: Coarctation
17.26: Robert Yates: Tetralogy of Fallot (ToF)
17.27: Sachin Khambadkone: Ebstein's Anomaly
17.28: Alessandro Giardini: Hypoplastic Left Heart Syndrome (HLHS)
17.29: Marc Gewillig: Single Ventricle/Total Cavopulmonary Connection (TCPC) (Fontan Circulation)
17.30: Marietta Charakida and John Deanfield: Total Anomalous Pulmonary Venous Connection (TAPVC)
17.31: John Deanfield and Marietta Charakida: Transposition of the Great Arteries (TGA)
17.32: Robert Yates and Marietta Charakida: Congenitally corrected transposition of the great arteries
Section 18. Prevention in cardiovascular disease and rehabilitation
Section editor: Massimo Piepoli
18.1: Massimo Piepoli: Introduction
18.2: Yvo M. Smulders, Marie-Therese Cooney, and Ian Graham: Cardiovascular risk estimation at the individual level
18.3: Guy De Backer, Johan De Sutter, and Ian M. Graham: Risk factor management at the level of the individual using lifestyle changes
18.4: Eva Prescott, Torben Jørgensen, Maja-Lisa Løchen, Jonathan Pearson-Stuttard, Simon Capewell, and Maja Lisa Løchen: Risk factor intervention at the population level
18.5: Ugo Corrà: Cardiac rehabilitation and exercise training
18.6: Ugo Corrà: Prevention in cardiovascular disease and rehabilitation
18.7: Christi Deaton, Margaret Cupples, and Kornelia Kotseva: Settings and stakeholders
Section 19. Diabetes mellitus metabolics syndrome
Section editor: Lars Ryden
19.1: Lars Ryden: Introduction
19.2: Jaakko Tuomilehto and Lars Ryden: Dysglycaemia - Definition, classification and diagnosis
19.3: Francesco Cosentino: Vascular complications to dysglycaemia
19.4: Nikolaus Marx: Cardiovascular risk assessment in dysglycaemic patients
19.5: Linda Mellbin and Lars Ryden: Preventing cardiovascular complications in patients with dysglycemia
19.6: Baris Gencer and Marco Roffi: Special conditions - Acute coronary syndromes
19.7: Miguel Sousa Uva: Special conditions - Revascularisation
19.8: Karl Swedberg: Special conditions - Heart failure
19.9: Heikki Huikuri and Lars Ryden: Diabetes and Arrhythmia
19.10: Lucia Mazzolai, Marianne Brodmann, and Victor Aboyans: Diabetes and lower extremity arterial disease
19.11: Henrik Per Groop and Drazenka Pongrac Barlovic: Kidney disease
19.12: Asa Hornsten: Person centred care
Section 20. Heart and the brain
Section editor: Hans-Christoph Diener
20.1: Hans-Christoph Diener: Acute ischaemic stroke: classification and diagnosis
20.2: Christoph Kleinschnitz: Impact of stroke on heart function
20.3: Stefan Hohnloser: Causes of cardioembolic stroke
20.4: Hans-Christoph Diener: Embolic stroke of undetermined source
20.5: Heinrich P. Mattle and Simon Jung: Treatment of acute stroke
20.6: David R. Holmes Jr, Guy S. Reeder, and Heinrich Mattle: Closure of a patent foramen ovale for the prevention of stroke
20.7: Hans-Christoph Diener: Secondary stroke prevention in patients with atrial fibrillation
20.8: Martin O'Donnell and Cliona Small: Management of vascular risk factors and co-morbidities in secondary stroke prevention
20.9: Heinrich Mattle, Marcel Arnold, and Urs Fischer: Intracranial haemorrhage in patients with atrial fibrillation on anticoagulants
20.10: Hans-Christoph Diener and John Camm: Atrial Fibrillation and dementia
Section 21. Cardiovascular problems in chronic kidney disease
Section editor: Christoph Wanner
21.1: Stephan Segerer and Harald Seeger: Epidemiology and chronic kidney disease as a cardiovascular risk factor
21.2: Thomas F. Mueller and Valerie Luyckx: Causes of death in renal disease
21.3: Christoph Wanner: Pathophysiology
21.4: Victoria Delgado: Cardiovascular imaging in chronic kidney disease
21.5: Stephan Segerer and Harald Seeger: Prevention and drug therapy in chronic kidney disease
21.6: Petra Nijst and Wilfried Mullens: Device therapy in chronic kidney disease (implantable cardioverter defibrillator, cardiac resynchronization therapy)
21.7: Thomas F. Mueller and Valerie Luyckx: Special considerations in patients undergoing renal replacement therapy and kidney transplant patients
Section 22. Erectile dysfunction
Section editor: Charalambos Vlachopoulos
22.1: Piero Montorsi: Sex and the heart
22.2: Michael Doumas and Chrysoula Boutari: Erectile dysfunction: definition and size of the problem
22.3: Tiny Jaarsma: Asking
22.4: Charalambos Vlachopoulos and Nikolaos Ioakeimidis: Erectile dysfunction as a marker and predictor of cardiovascular disease
22.5: Geoffrey Hackett: Testosterone, erectile dysfunction, and the heart
22.6: Kevan R. Wylie: Sexual function and dysfunction in women (and the effect for the couple)
22.7: Michael Kirby: Lifestyle issues
22.8: Mike Kirby and Jonny Coxon: Drugs
22.9: Odunayo Kalejaiye, Amr Abdel Raheem, and David Ralph: Surgery
22.10: Charalambos Vlachopoulos, Nikolaos Ioakeimidis, and Dimitris Tousoulis: Management of a patient with erectile dysfunction with or without known cardiovascular disease
Section 23. Lung Disease
Section editor: Martin Cowie
23.1: Kieran Rothnie and Jennifer Quint: Epidemiological relationships between respiratory and cardiovascular diseases
23.2: Antia Simonds: Long Term Oxygen Therapy/Ventilation and Cardiovascular outcomes in chronic lung and respiratory disease
23.3: Jennifer Quint: Effect of COPD treatment on CV outcome
23.4: Michael Polkey: Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD) (and heart failure)
23.5: William Man and Rachael Evans: Pulmonary rehabilitation in Chronic Lung Disease and Heart Failure
23.6: Olaf Oldenburg: Sleep apnoea: definition, prevalence and role in cardiovascular diseases
23.7: Melissa Lipford and Virend Somers: Sleep Related Breathing Disorders - Classification and diagnosis
23.8: Holger Woehrle and Michael Arzt: Diabetes and Arrhythmia
23.9: Bernardo Selim: Sleep apnoea - Treatment options and sleep/CV
23.10: Mark Miller, Anoop Shah, Nicholas Mills, and Dave Newby: Diabetes and lower extremity arterial disease
23.11: Samuel Verges and Patrick Levy: Kidney disease
Section 24. Gastrointestinal disease
Section editor: Gerhard Rogler
24.1: Gerhard Rogler: Introduction
24.2: Eduard F. Stange: Gut microbiome, metabolic syndrome, and atherosclerosis
24.3: Slayman Obeid, Melroy Miranda, and Thomas F. Lüscher: Gut microbiota and coronary artery disease
24.4: Giuseppe Rosano: The gut and cardiovascular diseases
24.5: Gerd A. Kullak-Ublick and Regina Krattinger: Intestinal absorption and drug levels
24.6: Felix Stickel, Matteo Montani, and Christian Datz: Chronic heart failure and liver function
24.7: Conall Morgan and Luc Mertens: Protein-losing enteropathy associated with heart disease
Section 25. Rheumatoid arthritis and the heart
Section editor: Thomas Lüscher
25.1: Thomas F. Lüscher: Introduction
25.2: Roland Klingenberg and Ulf Müller-Ladner: Mechanisms of inflammation
25.3: Luigi Marzio Biasucci and Giovanna Liuzzo: Inflammatory diseases: inflammation and cardiovascular disease
25.4: Oliver Distler and Caroline Ospelt: Rheumatoid arthritis: basic mechanisms in joints
25.5: Thomas F. Lüscher and Paul M. Ridker: Anti-inflammatory therapies for cardiovascular disease
25.6: Oliver Distler and Adrian Ciurea: Treatment aims in rheumatoid arthritis
25.7: Gerhard Rogler: Inflammatory bowel disease: basic mechanisms
25.8: Christian M. Matter, Stephan Winnik, and Gerhard Rogler: Inflammatory bowel disease and the heart
25.9: Alexander A. Navarini: Psoriasis
Section 26. Rheumatic heart disease
Section editor: Ferande Peters
26.1: Ferande Peters: Introduction
26.2: Liesl Zühlke: Epidemiology of acute rheumatic fever and rheumatic heart disease
26.3: Liesl Zühlke: Pathogenesis: from acute rheumatic fever to rheumatic heart disease
26.4: Antoinette Cilliers: Clinical features and diagnosis of acute rheumatic fever
26.5: Ferande Peters, Ruchika Meel, and Mohammed R. Essop: Echocardiography in acute rheumatic fever and rheumatic heart disease
26.6: Liesl Zühlke: Prevention and definitive therapy of acute rheumatic fever
26.7: Ferande Peters, Mpiko Ntsekhe, and Mohammed Essop: Chronic rheumatic disease
26.8: Mohammed Essop, Mpiko Ntsekhe, and Ferande Peters: Clinical scenarios in chronic rheumatic heart disease
26.9: Mohammed Essop: Therapeutic options in chronic rheumatic heart disease
Section 27. Cardio-oncology
Section editor: John Groarke
27.1: John Groarke: Introduction
27.2: Ersilia M. DeFilippis and Anju Nohria: Radiation-induced heart disease: surveillance and management
27.3: Cian P. McCarthy, Michael T. Osborne, and Tomas G. Neilan: Surveillance for cardiotoxicity in patients receiving potentially cardiotoxic chemotherapy
27.4: Daniela Cardinale and Carlo Maria Cipolla: Anthracycline-related cardiotoxicity: epidemiology, surveillance, prophylaxis, management, and prognosis
27.5: Torbjørn Omland: Trastuzumab-related cardiotoxicity: epidemiology, surveillance, management, prophylaxis, and prognosis
27.6: Mark Sweeney and Alexander Lyon: Cardiovascular complications of novel kinase inhibitors
27.7: Daniel J. Lenihan: Cardiovascular complications of novel multiple myeloma treatments
27.8: Daniel Perry, Megan Caram, and Monika Leja: Cardiovascular risk in men with prostate cancer
27.9: John Keaney: Cardiac arrhythmias and cancer therapies
Section 28. HIV
Section editor: Nombulelo P. Magula
28.1: Nombulelo P. Magula and Akira Singh: Introduction
28.2: Giuseppe Barbaro: Epidemiology of HIV-associated cardiovascular complications
28.3: Ntobeko A. B. Ntusi: HIV-associated cardiomyopathy and myocarditis
28.4: Rubeshan Perumal and Nombulelo P. Magula: Pericarditis and myopericarditis in HIV
28.5: Darrin Ryan Naidoo and Sherlina Kasipersad: Vascular disease: coronary, stroke, and peripheral vascular disease
28.6: Anastase Dzudie and Friedrich Thienemann: Pulmonary hypertension: definitions, classification, diagnosis, and management
28.7: Nombulelo P. Magula, Rubeshan Perumal, and Ruffin Apalata: Antiretroviral treatment
Section 29. Acute coronary syndromes
Section editor: Stefan James
29.1: Stefan James and Marco Roffi: Introduction
29.2: Michael Joner and Philipp Nicol: The plaque
29.3: Héctor Bueno: Epidemiology of acute coronary syndromes
29.4: Lene Rørholm Pedersen and Eva Prescott: General risk factors of acute coronary syndromes
29.5: Giovanna Liuzzo, Daniela Pedicino, and Filippo Crea: Pathophysiology of acute coronary syndromes
29.6: Robert Storey and William Parker: Thrombotic response
29.7: Pascal Vranckx: Development of myocardial infarction
29.8: Christian Mueller: Diagnosis and risk stratification of acute coronary syndromes
29.9: Marco Valgimigli and Marco Angelillis: Treatment of non-ST elevation acute coronary syndromes
29.10: Borja Ibanez and Sigrun Halvorsen: Treatment of ST elevation acute coronary syndromes
Section 30. Takotsubo syndrome
Section editor: Christian Templin
30.1: Christian Templin: Introduction
30.2: Abhiram Prasad: Incidence and definition of takotsubo syndrome
30.3: Leonarda Galiuto and Filippo Crea: Mechanisms of takotsubo syndrome
30.4: John D. Horowitz, Thanh Ha Nguyen, Sven Y. Surikow, Gao Jing Ong, Cher-Rin Chong, Dana K. Dawson, and Michael P. Frenneaux: Signal transduction pathways initiated by catecholamines in takotsubo syndrome: focus on nitrosative stress and energetic impairment
30.5: Jelena R. Ghadri: Triggers of takotsubo syndrome
30.6: Ilan Wittstein: Clinical presentation of takotsubo syndrome
30.7: Rodolfo Citro and Eduardo Bossone: Diagnostic testing in takotsubo syndrome
30.8: Federico Migliore, Sebastiano Gili, and Domenico Corrado: ECG features and arrhythmias in takotsubo syndrome
30.9: Ken Kato, Sebastiano Gili, Fabio Fabbian, and Roberto Manfredini: Co-morbidities in takotsubo syndrome
30.10: John E. Madias: Management of takotsubo syndrome
30.11: Scott W. Sharkey: Takotsubo syndrome complications, outcome, and prognosis
Section 31. Genetics of CV diseases
Section editor: William Wijns
31.1: William Wijns: Introduction
31.2: Michael Joner, Kristin Steigerwald, and Anna Bulin: Pathology of Stable Coronary Artery Disease
31.3: Nils Johnson and K. Gould: Pathophysiology of coronary circulation
31.4: Filippo Crea and Gaetano Lanza: Myocardial ischemia: definition and causes
31.5: Christian Seiler: Importance of the Coronary Collateral Circulation
31.6: Jeroen Bax: Coronary artery disease: from atherosclerosis to obstructive disease, inducible ischemia and the ischemic cascade
31.7: Ulrich Fischer-Rasokat and Christian Hamm: Clinical symptoms of stable ischemic heart disease
31.8: Juhani Knuuti and Antti Saraste: Non invasive functional evaluation
31.9: Stephan Achenbach: Non invasive (CT) and invasive angiography
31.10: Keith Oldroyd and Colin Berry: Invasive Functional Evaluation of Patients with Chronic Ischaemic Heart Disease
31.11: Nicola Ryan, Nieves Gonzalo, and Javier Escaned: Intracoronary imaging
31.12: Vasim Farooq, Patrick Serruys, and Ply Chichareon: Risk stratification and risk scores
31.13: Nicolas Danchin, Etienne Puymirat, and Nadia Aissaoui: Medical management: lifestyle and behavioural changes
31.14: Aviv Shaul and David Hasdai: Medical management: pharmacological therapy
31.15: Jean Claude Tardif, Philippe L?Allier, and Fabien Picard: Myocardial revascularization: symptomatic and prognostic indications
31.16: Ruben Osnabrugge and Pieter Kappetein: Cost Effectiveness
31.17: Ran Kornowski and Eli Lev: Patient Reported Outcome Measures in Cardiovascular Disease
31.18: Ruben Osnabrugge and Pieter Kappetein: IHD and Diabetes
31.19: Daniele Giacoppo and Robert Byrne: Percutaneous Coronary Intervention vs. Coronary Artery Bypass Grafting
31.20: Alessia Azzano and Stefan Verheye: Refractory angina
31.21: Ward Heggermont, Marc Vanderheyden, and Jozef Bartunek: Chronic ischemic cardiomyopathy
31.22: Paolo Camici and Ornella Rimoldi: Microvascular angina
31.23: Peter Ong and Udo Sechtem: Vasospastic angina
Section 32. Myocardial disease
Section editor: Perry Elliott
32.1: Perry Elliott: Introduction
32.2: Eloisa Arbustini, Valentina Favalli, Alessandro Di Toro, Alessandra Serio, and Jagat Narula: Classification of cardiomyopathies
32.3: Claudio Rapezzi and Massimiliano Lorenzini: General approach to diagnosis of cardiomyopathies
32.4: Mohammed Akhtar and Luis Lopes: Hypertrophic Cardiomyapathy - Genetics of HCM
32.5: Albert Hagege: Hypertrophic Cardiomyapathy - HCM: Diagnosis and assessment of symptoms
32.6: Iacopo Olivotto: Hypertrophic Cardiomyapathy - HCM: Medical management of heart failure symptoms and arrythmia
32.7: Steve Omen: Hypertrophic Cardiomyapathy - HCM: Invasive management of left ventricular outflow tract obstruction
32.8: Constantinos O'Mahony: Hypertrophic Cardiomyapathy - HCM: Prevention of sudden cardiac death
32.9: Luis Lopes: Dilated Cardiomyopathy - DM: Genetics
32.10: Gianfranco Sinagra, Marco Merlo, and Davide Stolfo: Dilated Cardiomyopathy - Clinical diagnosis and medical management
32.11: Pier Lambiase and Rui Providencia: Dilated Cardiomyopathy - DCM: Management of arrythmia and prevention of sudden cardiac death
32.12: Jens Mogensen: Restrictive cardiomyopathy
32.13: Petros Syrris and Alexandros Protonotarios: Arrhythmogenic right ventricular cardiomypathy - ARVC: Genetics
32.14: Cristina Basso, Barbara Bauce, and Gaetano Thiene: Arrhythmogenic right ventricular cardiomypathy - ARVC: Diagnosis
32.15: Perry Elliott and Alexandros Protonotarios: Arrhythmogenic right ventricular cardiomypathy - ARVC: Management of symptoms and prevention of sudden cardiac death
32.16: Pablo Garcia-Pavia and Fernando Dominguez: Left Ventricular non-compaction - LVNC: GENETICSand embryology
32.17: Jens Mogensen and Torsten B. Rasmussen: Left ventricular non-compaction: diagnosis and clinical management
32.18: Sabine Pankuweit: Myocarditis - Aetiology & histopathological diagnosis
32.19: Alida Caforio, Renzo Marcolongo, and Sabino Iliceto: Myocarditis - Clinical presentation
32.20: Ali Yilmaz and Anca Florian: Myocarditis - Imaging (Echo, CMR, nuclear)
32.21: Peter Heinz Schultheiss and Felicitas Escher: Myocarditis - Treatment of myocarditis
32.22: Denis Duboc: The Heart in Nueromuscular disease - Mitochondrial Disease
32.23: Henning Bundgaard, Anna Axelsson, Alex Christensen, and Helle Petri: The Heart in Nueromuscular disease - Myotonic Dystrophy
32.24: Karim Wahbi: The Heart in Neuromuscular disease - Duchenne and Limb Girdle Muscular Dystrophies
32.25: Ales Linhart: The Heart Inherited Metabolic disorders - Lysomal and glycogen storage diseases
32.26: Martha Grogan: Cardiac Amyloidosis
32.27: Karen Sliwa and Denise Hilfiker-Kleiner: Peripartum Cardiomyopathy
32.28: Juan Kaski and Gabrielle Norrish: Cardiomyopathies in Children and Adolescents
Section 33. Pericardial disease
Section editor: Yehuda Adler
33.1: Michael Arad and Yehuda Adler: Overview of pericardial syndromes
33.2: Massimo Imazio, Fiorenzo Gaita, and Yehuda Adler: Acute and recurrent pericarditis
33.3: Antonio Brucato and Stefano Maggiolini: Pericardial effusion
33.4: Arsen D. Ristic, Petar M. Seferovic, Bernhard Maisch, and Vladimir Kanjuh: Cardiac tamponade
33.5: Antonis Pantazis, Karin Klingel, and Yishay Wasserstrum: Constrictive pericarditis
33.6: Angelos G. Rigopoulos and Hubert Seggewiss: Pericardial masses and congenital abnormalities
33.7: Dor Lotan and Yehuda Adler: Pericardial involvement in neoplastic disease
33.8: Massimo Imazio and Fiorenzo Gaita: Multimodality imaging of pericardial diseases
33.9: Bernhard Maisch, Arsen Ristic, Sabine Pankuweit, and Peter Seferovic: Interventional therapies for pericardial diseases
33.10: George Krasopoulos: Surgical therapies for pericardial disease
33.11: Yehuda Adler and Dor Lotan: What next?
Section 34. Tumours of the heart
Section editor: Gaetano Thiene
34.1: Gaetano Thiene, Stefania Rizzo, Martina Perazzolo Marra, Marialuisa Valente, and Cristina Basso: Masses and cardiac tumours: classification and diagnosis
34.2: Cristina Basso, Stefania Rizzo, Martina Perazzolo Marra, Marialuisa Valente, and Gaetano Thiene: Benign cardiac tumours
34.3: Cristina Basso, Stefania Rizzo, Marialuisa Valente, Martina Perazzolo Marra, and Gaetano Thiene: Malignant tumours, pericardial tumours, and therapy
Section 35. Valvular heart disease
Section editor: Helmut Baumgartner
35.1: Bernard Lung and Pieter Kappetein: Introduction and general comments
35.2: Pilar Tornos Mas and Emmanuel Lansac: Aortic regurgitation
35.3: Helmut Baumgartner and Thomas Walther: Aortic stenosis
35.4: Raphael Rosenhek and Michele de Bonis: Mitral regurgitation
35.5: Alec Vahanian: Mitral stenosis
35.6: Patrizio Lancellotti and Michele de Bonis: Tricuspid regurgitation
35.7: Michele DeBonis: Tricuspid stenosis
35.8: Michele DeBonis: Combined and multiple valve diseases
35.9: Bernard Iung and Johan Sjögren: Prosthetic valves
35.10: Johan Holm and Bernard Iung: Management during non-cardiac surgery
35.11: Johan Holm and Bernard Iung: Management during pregnancy
Section 36. Infective endocarditis
Section editor: Gilbert Habib
36.1: Bernard Iung: Epidemiology and physiopathology
36.2: Nuria Fernández-Hidalgo, María Nazarena Pizzi, and Pilar Tornos: Diagnosis
36.3: Isidre Vilacosta and Carmen Olmos: Prognosis and complications
36.4: José A. San Román and Javier López: Prosthetic valve endocarditis
36.5: Maria Grazia Bongiorni and Andrea Di Cori: Cardiac device-related endocarditis
36.6: José A. San Román and Javier López: Right-sided infective endocarditis
36.7: Patrizio Lancellotti and Stella Marchetta: Non-bacterial thrombotic endocarditis
36.8: Joey M. Kuijpers, Berto J. Bouma, and Barbara J. M. Mulder: Specific situations: congenital heart disease
36.9: Gilbert Habib: Indications for surgery: guidelines
36.10: Jean-François Obadia, Benoit Cosset, and Matteo Pozzi: Surgical techniques
36.11: Bruno Hoen and Xavier Duval: Antibiotic prophylaxis and prevention of infective endocarditis
36.12: Gilbert Habib: Conclusion and future directions
Section 37. Heart failure
Section editor: John McMurray
37.1: Theresa McDonagh and Kaushik Guha: Epidemiology of Heart Failure
37.2: Pietro Aldo Maggioni and Ovidiu Chioncel: Definition, epidemiology/burden of disease - HFrEF
37.3: Lars Lund and Gianluigi Savarese: Definition, epidemiology/burden of disease - HFpEF
37.4: Anna Stromberg and Tiny Jaarsma: Health related quality of life - Definition, epidemiology, burden of disease, interventions
37.5: Pardeep Jhund: Heart Failure: Symptoms, signs and the ECG
37.6: Chronic Heart Failure Diagnosis a Heart Failure with preserved Ejection Fraction
37.7: Thomas Marwick: Chronic heart failure diagnosis - Imaging echocardiography
37.8: Robert Manka and Sabrina Oebel: Chronic heart failure diagnosis - Imaging - cardiac MRI
37.9: Christian Mueller: Chronic heart failure diagnosis - Biomarkers
37.10: Perry Elliott: Chronic heart failure diagnosis - Genetics
37.11: Vasiliki Bistola, John Parissis, and Gerasimos Filippatos: Estimating prognosis - Prognostic scores
37.12: Arthur Richards: Estimating prognosis - Biomarkers
37.13: Dipak Kotecha and Mitja Lainscak: Comorbidity (HFrEF and HFpEF) - Atrial fibrillation
37.14: Mark Petrie and Kieran Doherty: Heart failure and diabetes mellitus
37.15: Francesco Paneni and Massimo Volpe: Hypertension and Heart Failure
37.16: Kevin Damman: Comorbidity (HFrEF and HFpEF) - Renal dysfunction
37.17: Piotr Ponikowski: Comorbidity (HFrEF and HFpEF) - Anaemia/iron deficiency
37.18: Stefan Anker and Stephan von Haeling: Comorbidities: Obesity, cachexia, sarcopenia, and the impact of nutrition
37.19: Comorbidity (HFrEF and HFpEF) a Lung disease
37.20: Martin Cowie: Comorbidity (HFrEF and HFpEF) - Sleep disordered breathing
37.21: Thomas Suter: Comorbidity (HFrEF and HFpEF) - Cancer
37.22: Luc Pierard: Heart failure due to valvular heart disease
37.23: Rhondalyn Forde-McLean and Mariell Jessup: Diuretic Use in Heart Failure with Reduced Ejection Fraction
37.24: Marc Pfeffer: ACEI and or ARBs in Heart Failure and reduced Ejection Fraction
37.25: John McMurray: Angiotensin receptor-neprilysin inhibitors
37.26: Simon Beggs and Roy Gardner: Beta blockers in heart failure with reduced ejection fraction
37.27: Michel Komajda: HFrEF pharmacological treatment - Ivabradine
37.28: John Cleland and Yura Mareev: Heart Failure with a Reduced Left Ventricular Ejection Fraction (HFrEF) Pharmacological Treatment; Digitalis Glycosides
37.29: Faraz Ahmad and Clyde Yancy: HFrEF pharmacological treatment - Hydralazine and isosorbide dinitrate
37.30: Valentina Kutyifa: HFrEF other treatment - CRT/ICD
37.31: Eric Velazquez and Mark Petrie: HFrEF other treatment - Revascularization
37.32: Randall Starling and Emer Joyce: HFrEF other treatment - VADs
37.33: Peter MacDonald and Kumud Dhital: Advanced Heart Failure other treatment - Transplantation
37.34: Anna Stromberg and Tiny Jaarsma: HFrEF treatment - nurse led heart failure management programmes
37.35: Maja Cikes and Scott Solomon: HFpEF treatment - Pharmacological therapy
37.36: Dirk van Veldhuisen: Patient monitoring
37.37: Alan Cohen-Solal: Exercise Rehabilitation in Heart Failure with reduced and preserved Ejection Fraction
37.38: James Beattie: Palliative care in heart failure
37.39: Adriaan Voors and Piotr Ponikowski: Acute heart failure - Diagnosis
37.40: Javier Martin-Sanchez, Oscar Miro, and Hector Bueno: Acute heart failure - Immediate management/stabilization
37.41: Dimitrios Farmakis, John Parissis, and Gerasimos Filippatos: Acute heart failure - Treatment
Section 38. Bradycardia
Section editor: Giuseppe Boriani
38.1: Giuseppe Boriani: Introduction
38.2: Fredrik Gadler and Cinzia Valzania: Aetiology and epidemiology of bradyarrhythmias
38.3: Bulent Gorenek and Gulmira Kudaiberdieva: Classification of bradyarrhythmias
38.4: Georges H. Mairesse: Methods and tools for the diagnosis of intermittent and persistent bradycardia
38.5: Antonio Zaza: Anatomy and physiology of the sinus node
38.6: Bruce Wilkoff and Corey Coleman: The sinus node: normal and abnormal chronotropic response and drug effects
38.7: Jonathan M. Kalman and Gwilym M. Morris: Sinus node disease: pathophysiology and natural history
38.8: Tatjana Potpara: Sinus node disease: ECG patterns and diagnosis
38.9: Dominic A. M. J. Theuns: Sinus node disease: the role of electrophysiological testing
38.10: Atrial tachyarrhythmias in bradycardiaatachycardia syndrome: characterization and evolution
38.11: M. J. Pekka Raatikainen: Anatomy and physiology of the atrioventricular node
38.12: S. Serge Barold: Atrioventricular conduction abnormalities and atrioventricular blocks: ECG patterns and diagnosis
38.13: Demosthenes G. Katritsis and Mark E. Josephson: Atrioventricular conduction abnormalities and atrioventricular blocks: role of electrophysiology testing
38.14: Drago Fabrizio and Battipaglia Irma: Congenital atrioventricular blocks: clinical presentation, clinical evaluation, and management
38.15: Richard Sutton: Carotid sinus syndrome: clinical presentation, diagnosis, and management
38.16: Hein Heidbuchel: Bradycardia in athletes: clinical evaluation and management
38.17: Renato Pietro Ricci: Cardiac pacing: basic concepts
38.18: Alexander Bauer: Temporary pacing
38.19: Béla Merkely: Permanent cardiac pacing in bradyarrhythmias: device coding
38.20: Jens Cosedis Nielsen and Jens Kristensen: Pacing for bradycardia: device features and algorithms and clinical impact
38.21: Carsten Israel: Electrocardiographic patterns of cardiac pacemakers: normal and abnormal findings
38.22: Anne M. Gillis: Follow-up of pacemaker patients with bradyarrhythmias: scope of follow-up and organizational issues
38.23: Johannes Sperzel: Pacemakers in children and adolescents
38.24: Jean Claude Deharo: Lead management
38.25: Jan Steffel: Electromagnetic interference in pacemaker patients
38.26: Giuseppe Boriani and Igor Diemberger: Pacemaker syndrome
Section 39. Syncope
Section editor: Michele Brignole
39.1: J. Gert van Dijk and Roland D. Thijs: Definition, epidemiology, classification, and pathophysiology
39.2: Frederik J. de Lange and J. Gert van Dijk: Diagnostic evaluation
39.3: Jean-Claude Deharo: Reflex syncope
39.4: Richard Sutton: Cardiac syncope
39.5: Artur Fedorowski: Orthostatic intolerance: orthostatic hypotension and postural orthostatic tachycardia syndrome
39.6: Vincent Probst and Jean-Baptiste Gourraud: Unexplained syncope in patients with high risk of sudden cardiac death
39.7: Michele Brignole: Recommendations of the European Society of Cardiology Guidelines for the diagnosis and management of syncope (version 2018)
Section 40. Supraventricular tachycardias
Section editor: Carina Blomstorm-Lundqvist
40.1: Carina Blomström-Lundqvist: Introduction
40.2: Gregory Y. H. Lip: Epidemiology of supraventricular tachycardias
40.3: Tatjana Potpara: Atrial premature beats
40.4: Tatjana Potpara: Definitions, clinical presentation, symptoms, quality of life, and patient preferences
40.5: Haran Burri: Differential diagnosis of supraventricular tachycardias
40.6: Isabel Deisenhofer: Acute management of supraventricular tachycardias with and without established diagnosis (termination and/or rate regulation of tachycardia)
40.7: Isabel Deisenhofer: Management of rapid heartbeats/tachycardias with rhythm or rate control in the absence of ECG-verified diagnosis
40.8: Isabel Deisenhofer: Management of specific supraventricular tachycardias
40.9: Brian Olshansky: Sinus node-related tachycardias: physiological sinus tachycardia, inappropriate sinus tachycardia, sinus node reentrant tachycardia, and postural orthostatic tachycardia syndrome
40.10: Pierre Jaïs and Nicolas Derval: Atrial tachycardias: focal and multifocal atrial tachycardias
40.11: Jose L. Merino: Atrial tachycardias: macroreentrant atrial tachycardias, CTI-dependent atrial flutter (clockwise, anticlockwise), and non-CTI-dependent macroreentrant atrial tachycardia
40.12: Demosthenes G. Katritsis: Atrioventricular nodal reentrant tachycardia
40.13: Jonathan Chrispin and Hugh Calkins: Accessory pathways-related tachycardias: Wolff-Parkinson-White syndrome and atrioventricular reentrant tachycardias
40.14: Carlo Pappone and Vincenzo Santinelli: Concealed accessory pathways and related tachycardias
40.15: Hildegard Tanner: Permanent junctional reciprocating tachycardia
40.16: Carlo Pappone and Vincenzo Santinelli: Pre-excitation related to Mahaim physiology
40.17: Jonathan Chrispin and Hugh Calkins: Asymptomatic pre-excitation
40.18: Demosthenes G. Katritsis: Non-reentrant junctional tachycardias
40.19: Giuseppe Boriani: Health economy
Section 41. Atrial fibrillation
Section editor: John Camm
41.1: A. John Camm: Introduction
41.2: Emelia Benjamin and Darae Ko: Epidemiology
41.3: Ulrich Schotten: Mechanisms of atrial fibrillation: electrophysiological basis
41.4: David O. Arnar and Hilma Holm: Mechanisms of atrial fibrillation: genetics
41.5: David R. Van Wagoner: Mechanisms of atrial remodelling
41.6: Larissa Fabritz, Ulrich Schotten, and Paulus Kirchhof: Types of atrial fibrillation
41.7: Ben Freedman and Nicole Lowres: Silent atrial fibrillation
41.8: Justin G. L. M. Luermans, Jordi Heijman, Isabelle C. Van Gelder, and Harry J. G. M. Crijns: Atrial fibrillation progression and prevention
41.9: Hein Heidbuchel: Clinical investigation of patients presenting with atrial fibrillation
41.10: Christian Sticherling and Michael Kuehne: Management of acute presentation with atrial fibrillation rate control
41.11: Riccardo Cappato: Restoration of sinus rhythm: direct current cardioversion
41.12: Irina Savelieva: Pharmacological cardioversion for atrial fibrillation
41.13: Isabelle C. Van Gelder, Michiel Rienstra, Laurent Pison, and Harry J. G. M. Crijns: Rate control: medical therapy
41.14: Maurizio Gasparini and Paola Galimberti: Rate control: ablation and device therapy (ablate and pace)
41.15: Juan Tamargo: Rhythm control: antiarrhythmic drugs
41.16: Gerhard Hindricks, Nikolaos Dagres, Philipp Sommer, and Andreas Bollmann: Development of atrial fibrillation catheter ablation and ablation strategies
41.17: Chawannuch Ruaengsri, Matthew R. Schill, Richard B. Schuessler, and Ralph J. Damiano, Jr: Rhythm control: surgical ablation
41.18: Albert L. Waldo: Rate versus rhythm control therapy for atrial fibrillation: a perspective
41.19: Jeroen Hendriks: Follow-up of patients with atrial fibrillation
41.20: Gregory Y. H. Lip: Stroke risk factors and risk stratification in atrial fibrillation
41.21: Michael D. Ezekowitz and Amanulla N. Khaji: Stroke prevention in atrial fibrillation
41.22: Margaret C. Fang: Bleeding risk in anticoagulated patients with atrial fibrillation
41.23: Thorsten Lewalter, Clemens Jilek, and Peter Sick: Thromboprophylaxis in atrial fibrillation: device therapy and surgical techniques
41.24: Eric M. Riles and Melvin Scheinman: Classification and mechanisms of atrial flutter
41.25: Bhupesh Pathik and Jonathan M. Kalman: Atrial flutter: clinical presentation
41.26: Tilman Maurer, Christine Lemes, and Karl-Heinz Kuck: Atrial flutter: management
41.27: Johannes Brachmann: Atrial fibrillation and heart failure
41.28: Eduard Guasch and Lluís Mont: Atrial fibrillation and athletes
41.29: David Hirsh and Nanette Wenger: Atrial fibrillation in the elderly
41.30: Rohan S. Wijesurendra and Barbara Casadei: Atrial fibrillation after cardiopulmonary surgery
41.31: Hung-Fat Tse and Jo-Jo Hai: Atrial fibrillation and hypertension
41.32: Bernadette Biondi: Atrial fibrillation and hyperthyroidism
41.33: Rajiv Mahajan, Dennis H. Lau, and Prashanthan Sanders: Atrial fibrillation and obesity
41.34: Jared D. Miller and Hugh G. Calkins: Atrial fibrillation and sleep apnoea and chronic obstructive pulmonary disease
41.35: Ken Okumura and Hirofumi Tomita: Atrial fibrillation and chronic kidney disease
41.36: Jamie Conti, Mark Panna, and Michael Kaufmann: Atrial fibrillation in pregnancy
41.37: Sunil Kapur and Saurabh Kumar: Atrial fibrillation associated with adult congenital heart disease
41.38: Jeroen Hendriks: Integrated care management in atrial fibrillation
41.39: Deirdre A. Lane: Patient education
Section 42. Ventricular tachycardia
Section editor: Brian Olshansky
42.1: Nishant Verma and Bradley P. Knight: Classification of ventricular tachycardias
42.2: Sei Iwai and Jason Jacobson: Evaluation and acute management of wide QRScomplex tachycardia
42.3: Alfred E. Buxton: Classification and treatment of non-sustained ventricular tachycardia
42.4: Fernando M. Contreras-Valdes and Peter J. Zimetbaum: Sustained monomorphic ventricular tachycardia associated with structural heart disease: classification, assessment, and initial treatment
42.5: Akihiko Nogami: Bundle branch reentry tachycardia
42.6: Len Ganz: Electrical storm
42.7: Tilman Maurer,William G. Stevenson, and Karl-Heinz Kuck: Sustained monomorphic ventricular tachycardia: the role of catheter ablation
42.8: Victor Bazan, Enrique Rodriguez-Font, and Francis E. Marchlinski: Sustained and non-sustained ventricular tachycardia and no associated heart disease (idiopathic ventricular tachycardia)
42.9: L. Brent Mitchell: Polymorphic ventricular tachycardias including torsade de pointes
Section 43. Sudden Cardiac Death
Section editor: Gerhard Hindricks
43.1: Harry Rakowski and Arnon Adler: Epidemiology, underlying substrates
43.2: Pedro Brugada Terradellas and Juan Sieira: Arrhythmic mechanisms (bradycardia and tachycardia)
43.3: Efstathios Iliodromitis and Dimitrios Farmaksis: Risk stratification for sudden cardiac death - in the general population
43.4: Nikolaos Dagres and Gerhard Hindricks: Risk stratification for sudden cardiac death - in ischemic cardiomyopathy
43.5: Dietmar Baensch: Risk stratification for sudden cardiac death - in dilated cardiomyopathy
43.6: Wilhelm Haverkamp and Philipp Attanasi: Risk stratification for sudden cardiac death - in hypertrophic cardiomyopathy
43.7: Firat Duru and Corinna Brunckhorst: Risk stratification for sudden cardiac death - in right ventricular cardiomyopathy
43.8: Peter J. Schwartz and Lia Crotti: Risk stratification for sudden cardiac death - in primary electrical disorders
43.9: Juan Fernandez-Armenta, Antonio Berruezo, Juan Acosta, and Diego Penela: New techniques for risk assessment
43.10: Efstathios Iliodromitis and Dimitrios Farmaksis: Primary prevention of sudden cardiac death - in the general population
43.11: Luigi Di Biase, Jorge Romero, Andrea Natale, Ricardo Avendano, and Mario Garcia: Primary prevention of sudden cardiac death - in ischemic cardiomyopathy
43.12: Jens Cosedis Nielsen and Jens Kristensen: Secondary prevention of sudden cardiac death (in ischemic cardiomyopathy
43.13: Riccardo Cappato: Primary prevention of sudden death - in Idiopathic dilated cardiomyopathy
43.14: Riccardo Cappato: Secondary prevention of sudden cardiac death - in dilatedcardiomyopathy
43.15: Barry Maron: Primary prevention of sudden cardiac death - in hypertrophiccardiomyopathy
43.16: Wilhelm Haverkamp and Philipp Attanasio: Secondary prevention of sudden cardiac death - in hypertrophiccardiomyopathy
43.17: Katja Zeppenfeld and Sebastiaan Piers: Primary prevention of sudden cardiac death - in right ventricular cardiomyopathy
43.18: Katja Zeppenfeld and Sebastiaan Piers: Secondary prevention of sudden cardiac death - in right ventricular cardiomyopathy
43.19: Josep Brugada and Elena Arbelo: Primary prevention of sudden cardiac death - in primary electrical disorders
43.20: Josep Brugada and Elena Arbelo: Secondary prevention of sudden cardiac death - in primary electrical disorders
43.21: Arash Arya: Secondary prevention of sudden cardiac death - after catheter ablation of ventricular tachycardia
43.22: Gerhard Hindricks, Michael Kühl, and Nikolaos Dagres: The implantable cardioverter defibrillator. Conclusions on sudden cardiac death and future perspective
PART 4. Vascular disease
Section 44. Systemic hypertension
Section editor: Bryan Williams
44.1: Stefano Taddei, Rosa Bruno, Masi Stefano, and Anna Solini: Epidemiology and Pathophysiology of Hypertension
44.2: Gianfranco Parati: Classification of blood pressure and blood pressure measurement
44.3: Giovanni De Simone: Target organ damage and CVD risk and clinical evaluation of the hypertensive patient
44.4: Isabella Sudano: Secondary causes of hypertension
44.5: Bryan Williams: Blood pressure Thresholds for treatment and blood pressure treatment targets in hypertension
44.6: Francesco P Cappuccio: Sodium and potassium intake, blood pressure and cardiovascular prevention
44.7: Michel Burnier, Sverre Kjeldsen, Anthony Heagerty, and Bryan Williams: Drug treatment of hypertension
44.8: Felix Mahfoud: Device based treatment for hypertension
44.9: Enrico Agabiti Rosei, Maria Lorenza Muiesan, and Massimo Salvetti: Hypertension in Specific conditions / comorbidities
44.10: Thomas Kahan: Hypertension in Special situations
Section 45. Pulmonary Hypertension
Section editor: Marc Humbert
45.1: Marc Humbert: Introduction
45.2: Stephan Rosenkranz: Definition
45.3: Rogerio Souza, Jose Leonidas Alves, and Susana Hoette: Epidemiology
45.4: Christophe Guignabert, Ly Tu, Alice Huertas, and Marc Humbert: Pathophysiologic Mechanisms in Pulmonary Hypertension
45.5: Florent Soubrier, Melanie Eyries, Barbara Girerd, David Montani, David Tregouet, and Marc Humbert: Genes of pulmonary hypertension as major diagnostic tools
45.6: Joanne Groeneveldt, Anton Vonk Noordegraaf, and Frances de Man: Mechanisms of right ventricular failure
45.7: Marion Delcroix and Catharina Belge: Clinical Presentation of Pulmonary Hypertension
45.8: Marion Delcroix and Catharina Belge: Life-threatening complications of pulmonary hypertension
45.9: Rogerio Souza, Francisca Oleas, and Caio Fernandes: Clinical classification
45.10: Adam Torbicki: Echocardiographic findings in pulmonary hypertension
45.11: John Coghlan: Screening for pulmonary hypertension
45.12: Rogerio Souza, Daniela Calderaro, and Luis Felipe Prada: Diagnosis and clinical Investigation of patients presenting with pulmonary hypertension
45.13: Stephan Rosenkranz: Management of pulmonary hypertension - Basic treatment
45.14: Nazzareno Galie, Alessandra Manes, and Massimiliano Palazzini: Management of pulmonary hypertension: targeted therapies
45.15: Nazzareno Galie, Alessandra Manes, and Massimiliano Palazzini: Management of pulmonary hypertension - Treatment algorithm
45.16: Laurent Savale: Lung transplantation in pulmonary arterial hypertension
45.17: Rogerio Souza, Carlos Jardim, and Luciana Morinaga: Idiopathic pulmonary arterial Hypertension
45.18: Nicholas Morrell and Charaka Hadinnapola: Heritable pulmonary arterial Hypertension
45.19: Irene Lang and Meinhard Kneussl: Pulmonary arterial Hypertension induced by drugs and toxins
45.20: Chris Denton: Pulmonary arterial Hypertension associated with connective tissue disease
45.21: Olivier Sitbon and Laurent Savale: Portopulmonary Hypertension
45.22: Michael Gatzoulis, Margarita Brida, and Michel Gatzoulis: Pulmonary arterial Hypertension associated with congenital heart diseases
45.23: Olivier Sitbon: Pulmonary Arterial Hypertension associated with HIV infection
45.24: David Montani, Barbara Girerd, Edmund Lau, and Marc Humbert: Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatois
45.25: Jean-Luc Vachiery: Pulmonary hypertension due to left heart diseases
45.26: Ari Chaouat, Anne Guillaumot, Emmanuel Gomez, Olivier Huttin, Christine Suty-Selton, and Francois Chabot: Pulmonary hypertension due to chronic lung diseases
45.27: Gerald Simonneau: Chronic thrombo-embolic pulmonary hypertension
45.28: Andrew Peacock: Hypertension due to multiple and/or unclear mechanisms
45.29: Simon Gibbs: Referral centres and patient education
45.30: David Montani, Barbara Girerd, and Marc Humbert: Genetic counselling in pre-capillary pulmonary hypertension
45.31: Marius Hoeper: Risk assessment and treatment goals in patients presenting with pulmonary arterial hypertension
45.32: Marc Humbert: Conclusion
Section 46. Disease of the aorta
Section editor: Raimund Erbel
46.1: Raimund Erbel: Introduction
46.2: Raimund Erbel: The normal aorta
46.3: Oliver Gaemperli and Udo Sechtem: Aortic aneurysm - Thoracic aortic aneurysm - Diagnostic approach
46.4: Axel Haverich and Andreas Martens: Aortic aneurysm - Thoracic aortic aneurysm - Therapeutic options
46.5: Roberto Bartolomeo, Alessandro Leone, Luca Di Marco, and Davide Pacini: Aortic aneurysm - Aortic arch aneurysms
46.6: Regula von Allmen: Aortic aneurysm - Abdominal aortic aneurysm - Diagnostic Approach
46.7: Regula von Allmen: Aortic aneurysm - Abdominal aortic aneurysm - Therapeutic options
46.8: Yuvrajsinh Parmar and I. Kronzon: Aortic sclerosis - Clinical signs and diagnosis
46.9: Raimund Erbel: Aortic sclerosis - Therapy
46.10: Riccardo Gorla, Eduardo Bossone, and Raimund Erbel: Acute aortic syndrome - Diagnostic strategy and clinical features
46.11: Toru Suzuki, Riccardo Gorla, and Eduardo Bossone: Acute aortic syndrome - Emerging role of biomarker
46.12: Christoph Starck, Robert Hammerschmidt, and Volkmar Falk: Acute aortic syndrome - Aortic dissection - Ascending aortic dissection
46.13: Rachel Clough, Xun Yuan, and Chirstoph Nienaber: Acute aortic syndrome - Aortic dissection - Descending aortic dissection
46.14: Jae-Kwan Song: Acute aortic syndrome - Intramural Haematoma
46.15: Arturo Evangelista and Jose Rodriguez-Palomares: Acute aortic syndrome - Penetrating aortic ulcer
46.16: Johnny Steuer and Mario Lachat: Acute aortic syndrome - Traumatic aortic injury
46.17: Ivan Nunez-Gil and Gisela Feltes: Acute aortic syndrome - latrogenic aortic trauma
46.18: Dorien Schepers and Bart Loeys: Genetic diseases of the aorta - Chromosomal and inherited diseases
46.19: Bernard Lung: Genetic diseases of the aorta - Aortic diseases associated with bicuspid aortic valves
46.20: Folkert Meijboom and Gertjan Sieswerda: Genetic diseases of the aorta - Aortic diseases associated with bicuspid aortic valves
46.21: Rosangela Cocchia, Riccardo Gorla, and Eduardo Bossone: Aortitis - infectious and non-infectious diseases
46.22: Francesca Urgnani and Vicente Riambau: Aortic tumor
46.23: Udo Sechtem and Oliver Gaemperli: Long-term follow-up in patients with aortic diseases
46.24: Raimund Erbel: Role of aortic centers and aortic teams
Section 47. Trauma to the cardiovascular system
Section editor: Christoph Nienaber
47.1: Ibrahim Akin and Christoph A. Nienaber: Trauma to the cardiovascular system
Section 48. Non-cardiac surgery
Section editor: Steen Kristensen
48.1: Hans Erik Botker: Introduction and epidemiology
48.2: Jose Gonzalez-Juanatey: Preoperative evaluation - Surgical risk for cardiac events Functional capacity Risk indexes
48.3: Emmanuelle Duceppe and P.J. Devereaux: Preoperative evaluation - Biomarkers
48.4: Juhani Knuuti and Antti Saraste: Preoperative evaluation - Non Invasive testing
48.5: Hans Erik Botker: Preoperative evaluation - Angiography
48.6: Emmanuelle Duceppe and P.J. Devereaux: Risk reduction strategies - Perioperative management of cardiovascular medication, Beta-blockers, Ivabradine, a2 receptor agonists, ACE-inhibitors, ATII-antagonists, Calcium antagonists
48.7: Steen Kristensen, Michael Maeng, and Kurt Huber: Risk reduction strategies - Antiplatelet therapy; aspirin, P2Y12 inhibitors Anticoagulants: including NOACs,Withdrawal - continuation
48.8: Marco Roffi and Fabio Rigamonti: Coronary revascularization before non-cardiac surgery
48.9: Rodrigo Modolo and Ana Paula de Faria: Chronic Heart Failure / Hypertension
48.10: Bernard Iung and Luc Pierard: Non-cardiac surgery Valvular heart disease
48.11: Susanna Price and Evi Christodoulou: Specific diseases - Arrhythmias,VA, SupraVA, Bradyarrhythmias
48.12: Susanna Price: Specific diseases - Renal
48.13: Marco Roffi: Specific diseases - Neurological
48.14: Susanna Price: Specific diseases - Pulmonary
48.15: Luc Pierard: Peri-operative monitoring - TOE
48.16: Susanna Price: Perioperative Monitoring - Right Heart catherization
48.17: Susanna Price: Perioperative Monitoring - Glucose
48.18: Stefan De Hert: Perioperative Monitoring - Anesthesiology
48.19: Juhani Knuuti and Antti Saraste: Conclusions and recommendations
Section 49. Peripheral arterial diseases
Section editor: Victor Aboyans
49.1: V Aboyans: Introduction
49.2: Marie-Louise Bartelink: Epidemiology and risk factors
49.3: Lucia Mazzolai: General aspects
49.4: Jean Philippe Collet: Antithrombotic drugs in peripheral arterial diseases
49.5: Ross Naylor: Extracranial carotid and vertebral artery disease
49.6: Tina Conhert: Upper extremity artery disease
49.7: Martin Björck: Mesenteric artery disease
49.8: Charalambos Vlachopoulos: Renal artery disease
49.9: Marianne Brodmann: Lower extremity artery disease
49.10: Marco DeCarlo: Multisite artery disease
49.11: Michal Tendera: Cardiac conditions in peripheral arterial diseases
49.12: JB Ricco: Gaps in evidence
Section 50. Venous thromboembolism
Section editor: Stavros Konstantinides
50.1: Stavros Konstantinides: Introduction
50.2: Alexander Cohen, Marjolein Brekelmans, and Carlos Martinez: Epidemiology and socio-economic consequences of VTE
50.3: Willem Lijfering and Suzanne Cannegieter: Predisposing factors for first and recurrent venous thrombosis
50.4: Dieuwertje Ruigrok and Anton Vonk Noordegraaf: Pathophysiology
50.5: Piotr Pruszczyk: Diagnosis - clinical prediction rules and laboratory tests
50.6: Helia Robert-Ebadi, Gregoire Le Gal, and Marc Righini: Diagnosis of acute pulmonary embolism and evolving imaging modalities
50.7: Cecilia Becattini and Giancarlo Agnelli: Prognostic assessment
50.8: Thomas Vanassche and Peter Verhamme: Treatment - haemodynamic and respiratory support
50.9: Cecilia Becattini and Giancarlo Agnelli: Treatment - anticoagulation
50.10: Guy Meyer: Treatment - thrombolysis
50.11: Ronald Winokur and Akhilesh Sista: Venous thromboembolism; Catheter Based Intervention and Inferior Vena Cava Filters
50.12: Thijs van Mens and Saskia Middeldrop: Management of PEin pregnancy
50.13: Cihan Ay and Florian Posch: Management of PEin patients with cancer
50.14: Marc Rodger, Lisa Duffett, and Faizan Khan: Venous thrombosis: Risk of recurrence and optimal duration of anticoagulation
50.15: Irene Lang,Walter Klepetko, and Hiromi Matsubara: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Section 51. Venous disease
Section editor: Sebastien Schellong
51.1: Eberhard Rabe and Felizitas Pannier: Epidemiology and classification of venous disease
51.2: Frederikus Klok, Charlotte Dronkers, and Menno Huisman: Venous imaging
51.3: Jochen Grommes: Venous recanalisation
51.4: Roshan Bootun, Tristan Lane, and Alun H. Davies: Varicose veins
51.5: Robert Eberhardt and Joseph Raffetto: Chronic veous insufficiency/postthrombotic syndrome
PART 5. Specific Populations - gender and race
Section 52. Cardiovascular disease in women
Section editor: Noel Bairey Merz
52.1: JoAnn E. Manson and Mariana Garcia: Background
52.2: Eva Prescott: Sex and gender difference overview
52.3: Karin Schenck-Gustafsson: Traditional cardiovascular disease risk factors
52.4: Angela H. E. M. Maas: Non-traditional cardiovascular disease risk factors unique to or predominant in women
52.5: Janet Wei: Cardiovascular disease prevention guidelines
52.6: Martha Gulati: Ischaemic heart disease in women
52.7: Vera Regitz-Zagrosek: Heart failure in women
52.8: Sharon Mulvagh: Valvular heart disease
52.9: Puja K. Mehta: Cardiac rehabilitation
52.10: Mariana Garcia: Peripheral arterial disease in women
52.11: C. Noel Bairey Merz: Future directions
Section 53. Pregnancy and heart disease
Section editor: Vera Regitz-Zagrosek
53.1a: Janet Wei and C. Noel Bairey Merz: General considerations
53.1b: Petronella Pieper: Pregnancy risk assessment
53.2: Lisa-Antonia Droege and Wolfgang Henrich: Gynaecological, obstetric, and neonatological aspects
53.3a: Jolien Roos-Hesselink and Annemien van den Bosch: Congenital heart disease and pulmonary hypertension
53.3b: Bernard Iung: Aortic diseases
53.4: Petronella G. Pieper and Bernard Iung: Valvular heart disease
53.5: Angela H. E. M. Maas: Ischaemic heart disease in pregnancy
53.6: Bozena Ostrowska, Barbara Kommata, Helena Malmborg, and Carina Blomström Lundqvist: Arrhythmias in pregnancy
53.7: Vera Regitz-Zagrosek: Cardiomyopathies and heart failure
53.8: Renata Cifkova: Hypertensive disorders
53.9: Karen Sliwa and Mark R. Johnson: Venous thromboembolism in the peripartum period
53.10: Stefan Verlohren: Drugs during pregnancy and breastfeeding
Section 54. Ethnicity
Section editor: Gregory H. Y. Lip
54.1: Amitava Banerjee: Global perspectives of hypertension and cardiovascular disease
54.2: Nizal Sarrafzadegan and Farzad Masoudkabir: Ethnicity and cardiovascular risk factors
54.3: Adam Timmis: Ethnicity and coronary artery disease
54.4: Bert-Jan van den Born and Charles Agyemang: Ethnicity and hypertension
54.5: Tatjana Potpara: Ethnicity and cardiac arrhythmias
54.6: Amitava Banerjee: Ethnicity and heart failure
54.7: Larissa Fabritz: Ethnicity and inherited cardiac disease
54.8: Bernard M. Y. Cheung and Esther W. Chan: Ethnic differences in responses to cardiovascular drugs
PART 6. Other aspects
Section 55. Sports and heart disease
Section editor: Antonio Pelliccia
55.1: Michael Papadakis and Sanjay Sharma: Cardiovascular adaptation to exercise and sport (according to type of sport, gender, and ethnicity)
55.2: Clinical assessment of the athleteas heart: normal and abnormal ECGs in athletes
55.3: Antonio Pelliccia and Stefano Caselli: Imaging testing for differential diagnosis of the athlete's heart from structural cardiac diseases
55.4: Eduard Guasch, Hein Heidbuchel, and Lluís Mont: Sudden cardiac death in athletes: implications for pre-participation evaluation and safety in sport arenas
55.5: Massimo Piepoli: Exercise and sport in the management of cardiovascular diseases (ischaemic heart disease, heart failure, and hypertension)
Section 56. Elderly
Section editor: Franz Messerli and Tomasz Grodzicki
56.1: Tomasz Grodzicki, Karolina Piotrowicz, and Jonna Sulicka: Multimorbidity and polypharmacy in the elderly with cardiovascular diseases
56.2: Piotr Sobanski: Palliative and end-of-life care in elderly subjects with CVD
56.3: Timo Strandberg and Tuomo Nieminen: Dementia and CVD
56.4: Antonio Cherubini and Massimiliano Fedecostante: Frailty, Sarcopenia and Falls and CVD
56.5: Nicola Veronese, Ludovico Carrino, and Stefania Maggi: Socio-economic issues and CVD (with emphasis on the caregivers)
56.6: Andreas Schoenenberger: Comprehensive geriatric assessment in CVD
56.7: Edgar Argulian: Degenerative cardiovascular disease in elderly
56.8: Stefano Rimoldi: Lessons from ESCGuidelines
56.9: Jerzy Gasowski, Chirag Bavishi, and Franz Messerli: Arterial Stiffness. From Isolated Systolic Hypertension to Syncope
56.10: Joanna Kostka, Malgorzata Koziarska-Rosciszewska, and Tomasz Kostka: Elderly. Special situations (sport, physical activity, travel)
56.11: Adrian Messerli and Khaled Ziada: Interventional Cardiology for the Elderly
Section 57. Precision medicine
Section editor: Paulus Kirchhof
57.1: Paulus Kirchhof: Foundations of personalised medicine
57.2: T. Kessler and Heribert Schunkert: Personalized management of coronary artery disease
57.3: Karin Sipido and Tom Guzik: Disease mechanisms guiding therapy
57.4: Larissa Fabritz, Eduard Guasch, Moritz Sinner, and Paulus Kirchhof: Personalised management of atrial fibrillation
57.5: Stephan Baldus and Henrik ten Freyhaus: Individualized valve therapy
57.6: Marina Cerrone, Morten Schak Nielsen, and Mario Delmar: Genetically-modified animals as tools to personalize the study of arrhythmia mechanisms and treatment
57.7: Simon de Denus, Marie-Pierre Dubé, and Jean-Claude Tardif: Opportunities for personalized approaches in heart failure
57.8: Andrea Mazzanti and Silvia Priori: Personalized Therapies for Cardiac Channelopathies
Section 58. Decision making and the heart team
Section editor: Patrick Serruys
58.1: Vasim Farooq and Patrick W. Serruys: The Heart Team: introduction
58.2: Vasim Farooq: Heart Teams in coronary artery disease
58.3: Mohammad Abdelghani, Fahd Makhdom, and Nicolo Piazza: Decision-making and Heart Teams in valvular heart disease: the transcatheter aortic valve implantation team model
58.4: Manuel Castella, Hans-Christoph Diener, Gerhard Hindricks, and Paulus Kirchhof: Heart Teams in atrial fibrillation
58.5: Mohammad Abdelghani, Martina Nassif, Nico A. Blom, David R. Koolbergen, Barbara J. M. Mulder, and Robbert J. de Winter: Heart Teams in grown-up congenital heart disease
58.6: Andras P. Durko, Stuart J. Head, and David P. Taggart: The Heart Team: conclusions and future perspectives
Section 59. Psychological factors and heart disease
Sectione editor: Susanne Pedersen
59.1: Susanne Pedersen: Introduction
59.2: Susanne Pedersen: Psychological factors and incident heart disease
59.3: Frank Doyle: Psychological impact of heart disease
59.4: Nina Kupper and Johan Denollet: Impact of psychological factors on outcomes
59.5: Roland von Kaenel and Christian Albus: Mechanisms: psychological factors and outcomes
59.6: Johan Denollet: The wider psychosocial context
59.7: Interventions: what works for whoma
59.8: Kim Smolderen: Clinical implications and future perspectives
59.9: Susanne Pedersen: Conclusions
59.10: Likely developments over the next 5a10 years
59.11: Susanne Pedersen: Personal perspective
Section 60. Interpretation of clinical trials
Section editor: John Cleland
60.1: John Cleland: Trial Design from a Clinical Perspective
60.2: Tim Friede: Clinical Trial Design: Statistical Issues
60.3: Muthiah Vaduganathan and Scott Solomon: Reporting Cardiovascular Clinical Trials
60.4: Jan Tijssen: Principles and methods of intervention research
60.5: Pardeep Jhund and John McMurray: Interpretation-2
60.6: Colin Baigent and Natalie Staplin: Meta-analysis
Section 61. Environment
Section editor: Thomas Münzel
61.1: Thomas Münzel, Sanjay Rajagopalan, Mette Sørensen, Dave Newby, and Robert D. Brook: Summary
61.2: Thomas Münzel, Sanjay Rajagopalan, Mette Sørensen, Dave Newby, and Robert D. Brook: Introduction
61.3: Thomas Münzel and Mette Sørensen: Pathophysiology of noise-induced cardiovascular diseases
61.4: Robert D. Brook, David Newby, and Sanjay Rajagopalan: Pathophysiology of air pollution-mediated cardiovascular events
61.5: Mette Sørensen and Thomas Münzel: Epidemiology of traffic noise and cardiometabolic disease
61.6: Robert D. Brook, David Newby, and Sanjay Rajagopalan: Epidemiology of air pollution and cardiometabolic diseases
61.7: Thomas Münzel, Sanjay Rajagopalan, Mette Sørensen, Dave Newby, and Robert D. Brook: Strategies to mitigate cardiovascular effects of noise and air pollution
61.8: Thomas Münzel, Sanjay Rajagopalan, Mette Sørensen, Dave Newby, and Robert D. Brook: Future perspectives
61.9: Thomas Münzel, Sanjay Rajagopalan, Mette Sørensen, Dave Newby, and Robert D. Brook: Conclusions
61.10: Thomas Münzel, Sanjay Rajagopalan, Mette Sørensen, Dave Newby, and Robert D. Brook: Development and challenges over the next decade
Section 62. Occupational and regulatory aspects
Section editor: Demosthenes Katritsis
62.1: Demosthenes G. Katritsis, Mark Anderson, and Michael M. Webb-Peploe: Occupational risk factors for heart disease
62.2: Demosthenes G. Katritsis, Mark Anderson, and Michael M. Webb-Peploe: Regulations concerning individual risk and public safety
Section 63. Economics and cost-effectiveness
Section editor: Lorenzo Mantovani
63.1: Lorenzo Mantovani: Introduction to health economics and cost-effectiveness of cardiovascular prevention
63.2: Dyfrig Hughes: Health and economic impact of non-adherence to preventative cardiovascular medicines
63.3: Giuseppe Boriani, Lucia D'Angiolella, and Fabiana Madotto: Economics of new therapies in electrophysiology
63.4: Zaher Fanari, Sandra Weiss, and William S. Weintraub: Medical economics and interventional cardiology
63.5: Lorenzo Mantovani and Lucia S. D'Angiolella: Economics of new therapies for heart failure, atrial fibrillation, and hypercholesterolaemia
PART 7. Appendices
A.1: Ian Graham, Marie Therese Cooney, Dirk De Bacquer, and Maryam Kavousi: Cardiovascular disease risk estimation
A.2: Polly Mitchell, Andrew Wragg, and Adam Timmis: Patient reported outcome measures

Προδιαγραφές προϊόντων

Εκδότες	Oxford University Press
Εξώφυλλο	Σκληρό
Σελίδες	2408
Έκδοση	3η
Ημ. Έκδοσης	December 2018

Γράψτε τη δική σου αξιολόγηση

Μόνο οι εγγεγραμμένοι χρήστες μπορούν να γράψουν σχόλια

Τίτλος κριτικής:

Κείμενο κριτικής:

Βαθμολογία:

Κακή
Άριστη

Ονοματεπώνυμο

Το email σας

Μήνυμα

Προδιαγραφές προϊόντων

Εκδότες	Oxford University Press
Εξώφυλλο	Σκληρό
Σελίδες	2408
Έκδοση	3η
Ημ. Έκδοσης	December 2018
ISBN	9780198784906

The ESC Textbook of Cardiovascular Medicine

New to this Edition:

New to this Edition:

Σχετικά με εμάς

Πληροφορίες

Ο λογαριασμός μου

Επικοινωνία